Last reviewed by Dr. Dharmender Malik on 14 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.
Introduction
Radioligand therapy — the use of receptor-targeted small molecules linked to therapeutic radionuclides — is now established practice in metastatic prostate cancer (Lu-177 PSMA-617 / Pluvicto) and somatostatin-receptor-positive neuroendocrine tumours (Lu-177 DOTATATE / Lutathera). The therapies are increasingly available across the United States, the European Union, and India. The published cost figures, however, vary by a factor of more than 5x across these jurisdictions, and online comparisons routinely conflate list price, out-of-pocket cost, and bundled service cost. This article reproduces sourced cost figures from each jurisdiction's primary references and explains what shifts between them — so that a patient considering treatment in any country can read a quote with informed eyes.
Scope and methodology of this comparison
AI Overview · short answer
The published list price of branded Pluvicto (Lu-177 PSMA-617) in the United States has been reported at approximately USD 42,500 per cycle pre-discount and pre-insurance, supported by Drugs.com and GoodRx pricing databases[1][2]. With a typical course of six cycles, the headline US list price approaches USD 255,000 before insurance, manufacturer assistance, or other discounts apply. In the European Union, individual member-state pricing has been negotiated separately under national reimbursement frameworks (NHS England, HAS France, AIFA Italy, G-BA Germany), with patient out-of-pocket exposure typically substantially lower than in the US private system[3]. In India, per-cycle costs are meaningfully lower than US list pricing — though specific figures vary by centre and isotope source (BRIT-domestic versus international supply versus branded Pluvicto) and should be obtained as an itemised written quote from the treating centre[4].
This article uses publicly accessible primary-source list pricing data for two licensed radioligand therapies:
- Lu-177 PSMA-617 (Pluvicto) — FDA-approved March 2022 for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), label expanded March 2025[5].
- Lu-177 DOTATATE (Lutathera) — FDA-approved January 2018 and EMA-approved September 2017 for somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs)[6].
The sources used for sourced figures in this article include: the FDA Drugs@FDA database; the Drugs.com Pluvicto Price Guide; GoodRx pricing data; the NCBI/NIH Bookshelf monograph on Pluvicto (NBK596311); Novartis Patient Support resources; EMA Pluvicto and Lutathera Summaries of Product Characteristics (SmPC); national reimbursement publications from NHS England (NICE TA), France (HAS), and Germany (G-BA); and published Indian institutional cohort literature (AIIMS New Delhi, Tata Memorial, Mittal et al. audits). Every price quoted in this article is referenced to its primary source[1][7].
Caveats applied throughout: list price is not the same as patient out-of-pocket cost; figures change over time and should be confirmed at the time of decision; centre quotes should always be obtained as written itemised documents.
United States — published list price and how it appears in practice
The published list price of Pluvicto in the United States has been reported at approximately USD 42,500 per cycle pre-discount across multiple public-facing sources[1][2]:
- Drugs.com Pluvicto Price Guide reports cash pricing around USD 42,500 per cycle for a single Pluvicto vial, with the published note that “this is the cash price and may not reflect insurance pricing”[1].
- GoodRx lists similar order-of-magnitude pricing with coupon-based discounts applicable in selected pharmacy settings[2].
- NCBI Bookshelf monograph NBK596311 — the comprehensive Pluvicto reference — discusses cost-of-treatment context and references the per-cycle list price[8].
- Novartis Patient Support provides coverage and copay assistance pathways for eligible US patients[9].
The headline figure (~USD 42,500/cycle) reflects the manufacturer's list price for the radiopharmaceutical itself. What a US patient actually pays out-of-pocket depends on: insurance coverage (Medicare Part B for outpatient infusion administration, commercial insurance with prior authorisation, or self-pay); copay assistance through Novartis Patient Support; secondary insurance; deductible status; site-of-care surcharges; and the cost of separately billed services including Ga-68 PSMA PET-CT eligibility imaging, post-administration imaging, infusion-suite charges, and professional fees[9][10].
Across a typical six-cycle treatment course, the cumulative list-price exposure approaches USD 255,000 pre-insurance and pre-assistance. The patient-facing out-of-pocket figure is substantially lower for most Medicare and well-insured commercial patients, and substantially higher for self-pay and underinsured patients[11].
European Union — reimbursement-led pricing
The European Union's pricing landscape for radioligand therapy differs structurally from the United States. Pluvicto received EMA approval in December 2022, and member-state pricing is set through national reimbursement frameworks rather than a single EU-wide list price[12]:
- NHS England (NICE TA940) — the National Institute for Health and Care Excellence published guidance on Lu-177 PSMA-617 in May 2024, including a commercial arrangement (confidential discount) between Novartis and NHS England such that the therapy is reimbursed under specified conditions[13].
- HAS France — the Haute Autorité de Santé has assessed Pluvicto with a favourable but conditional recommendation, with national pricing negotiated through the Comité Économique des Produits de Santé (CEPS)[14].
- G-BA Germany — the Federal Joint Committee has issued early benefit assessment for Pluvicto under AMNOG, with statutory health insurance covering the therapy[15].
- AIFA Italy — conditional reimbursement with reported managed-entry-agreement structures[16].
Patient out-of-pocket exposure in EU member states with comprehensive statutory or national health systems is generally low or zero for the radioligand itself, with co-payment exposure limited to nominal hospital or imaging copays. The headline EU list prices have been the subject of confidential negotiation and are not typically published in full[3].
India — per-cycle costs and what drives them
In India, per-cycle costs for Lu-177 PSMA-617 therapy vary by centre and by the isotope-source and bundle decisions discussed in our companion article on Lu-177 PSMA therapy cost considerations in India[4]. The principal drivers of Indian per-cycle cost variation are:
- Isotope source — Indian centres use Lu-177 from the Board of Radiation and Isotope Technology (BRIT, domestic) or international suppliers (ITM Germany, IDB Holland), or branded Pluvicto where supply is available. Domestic BRIT supply is meaningfully lower-cost than international supply, which is in turn meaningfully lower-cost than branded Pluvicto[17].
- Compounding versus branded product — Indian centres often compound Lu-177 PSMA-617 in-house or through partner radiopharmacy facilities under DCGI permissions and AERB licensure. Indian institutional cohorts (Yadav et al., AIIMS; Basu et al., BARC; others) have reported PSA response and survival outcomes consistent with international VISION-trial data using such compounded preparations[18].
- What is bundled — eligibility Ga-68 PSMA PET-CT, post-administration SPECT/CT or PET dosimetry, hospital admission, professional fees, pre-cycle workup, and supportive medications. The per-cycle quote should be itemised in writing[4].
- Centre overhead — institutional cost structures vary by centre type (public tertiary, private corporate hospital, specialty centre).
Patients should obtain itemised written quotes from treating centres, compare bundle-to-bundle (not headline-to-headline), and verify isotope source, AERB licensure, qualified personnel, and quality of multidisciplinary review — cost alone is not the right comparison. The full framework for evaluating an Indian quote is described in the companion article[4].
Side-by-side comparison: what shifts and why
| Component |
United States |
European Union (representative) |
India |
| Headline per-cycle list price (radiopharmaceutical only) |
~USD 42,500[1] |
Confidentially negotiated; reimbursed by national systems[3] |
Meaningfully lower; written itemised quote required[4] |
| Course of six cycles (radiopharmaceutical only) |
~USD 255,000 pre-insurance |
Largely covered by statutory / national insurance |
Centre-specific; obtained from itemised quote |
| Patient out-of-pocket typical exposure |
Variable; Medicare/insurance + Novartis Patient Support assistance |
Low/zero in member states with comprehensive statutory cover |
Self-pay common; private health insurance variable |
| What's typically bundled |
Drug + administration; ancillary imaging often separately billed |
Bundled within national health system framework |
Variable; itemised quote required |
| Insurance pathways |
Medicare Part B, commercial insurance with prior auth |
National health systems |
Indian private health insurance variable; international policies variable for overseas care |
| Charitable / manufacturer assistance |
Novartis Patient Support[9] |
National frameworks |
Centre-by-centre arrangements |
The implication: simple cross-currency comparison of headline figures is misleading. The same therapy in the same patient produces meaningfully different out-of-pocket experiences across jurisdictions because of insurance design, reimbursement structure, and the underlying isotope-supply and compounding pathway used.
What's bundled differently across jurisdictions
The radiopharmaceutical itself is only part of the cost-of-care picture. Across jurisdictions, the following components are bundled or unbundled differently[19]:
- Eligibility Ga-68 PSMA-11 PET-CT — pre-treatment imaging to confirm PSMA expression and define disease distribution. Costs and reimbursement vary substantially.
- Post-administration imaging — Y-90 / Lu-177 SPECT/CT or PET dosimetry imaging following each cycle.
- Hospital admission — some jurisdictions and centres admit patients overnight for radiation safety and monitoring; others deliver as outpatient.
- Professional fees — nuclear medicine physician, medical physicist, radiation safety officer time across consent, administration, and follow-up.
- Concurrent supportive therapy — renoprotective amino acid infusion (for Lu-177 DOTATATE), anti-emetics, bone-targeted agents.
- Inter-cycle re-staging — imaging at typically 3-4 cycles depending on centre protocol.
- Follow-up after course completion — biochemistry, imaging, and multidisciplinary review extending months after the last cycle.
An apples-to-apples comparison across jurisdictions must price all of these components in or out consistently. The headline figure for the radiopharmaceutical alone does not tell the comparison story.
A second therapy worth noting: Lu-177 DOTATATE (Lutathera)
Many patients researching radioligand therapy encounter Pluvicto and Lutathera in adjacent results. Lu-177 DOTATATE (Lutathera) is the somatostatin-receptor-targeting radioligand approved for GEP-NETs based on the NETTER-1 randomised trial[20]. Its cost structure shows similar cross-jurisdictional patterns to Pluvicto:
- US list pricing has been reported at approximately USD 47,500 per cycle (Drugs.com and GoodRx public data), with a typical course of four cycles[21].
- EMA approval (September 2017) and member-state reimbursement frameworks similar to those for Pluvicto[22].
- Indian per-cycle costs meaningfully lower than US list pricing, with similar drivers (isotope source, compounding, bundle composition).
For NET patients specifically, our companion article on neuroendocrine tumor treatment covers the clinical context.
Insurance and out-of-pocket realities
Patient-facing out-of-pocket cost — the figure that actually matters to most patients — depends on a combination of jurisdiction-specific factors[23]:
- US Medicare — Pluvicto is administered as an outpatient infusion, covered under Medicare Part B with 20% coinsurance after deductible. Medicare Supplement (Medigap) or Medicare Advantage plans modify the out-of-pocket exposure.
- US commercial insurance — prior authorisation typically required; out-of-pocket varies with plan design, deductible status, network site of care, and copay structure.
- US Novartis Patient Support — eligibility-based copay assistance and patient navigation services[9].
- European national systems — for member states with comprehensive statutory or national health coverage, out-of-pocket is generally low or zero for the radiopharmaceutical itself.
- Indian private health insurance — coverage variable by policy; pre-authorisation requirements should be confirmed with the insurer; some centres operate cashless arrangements with specific insurers, others on reimbursement basis[24].
- International patients in India — home-country insurance coverage of overseas care varies; some policies cover overseas radioligand therapy, others do not. Specific arrangements should be confirmed with the insurer and treating centre.
- Self-pay — the figure relevant when no insurance or assistance applies; particularly common for international patients in India.
Why direct cross-currency comparisons mislead
A frequent online pattern is the side-by-side comparison “Pluvicto in the US costs $X, in India it costs $Y, you save Z%.” This comparison structure is misleading for several reasons[25]:
- List price is not patient cost. A US patient with Medicare or strong commercial insurance pays a small fraction of list price out-of-pocket. The headline US figure is an insurer-facing number, not a patient-facing one in most cases.
- Bundles vary. A US quote may include or exclude imaging, hospital admission, and follow-up differently from an Indian quote. Bundle composition affects total course cost meaningfully.
- Isotope source and product type differ. Indian centres often deliver compounded Lu-177 PSMA-617; some US centres deliver branded Pluvicto. Both are clinically established, with overlapping outcomes data, but they are not identical products commercially.
- Travel and accommodation costs. International patients in India incur travel, accommodation, intercurrent illness, and lost-wage costs that are not in the per-cycle quote.
- Quality of clinical governance, dosimetry, and integrated multidisciplinary review. These are part of the value of care — not just the price — and should weigh in any centre comparison alongside cost.
The honest comparison is bundle-to-bundle and outcome-to-outcome, with centre quality factors weighed alongside cost.
How to evaluate a quote — the bundle-to-bundle method
The practical method for comparing radioligand therapy quotes across centres — whether within India or internationally — is bundle-to-bundle line-itemisation. For each candidate centre, obtain in writing[26]:
- Radiopharmaceutical source (BRIT domestic, ITM/IDB international, or branded product) and prescribed activity per cycle (GBq and mCi)
- Eligibility imaging cost (Ga-68 PSMA PET-CT or Ga-68 DOTATATE PET-CT)
- Post-administration imaging cost (SPECT/CT or PET dosimetry)
- Hospital admission charges (room, nursing, radiation safety surcharge)
- Professional fees (nuclear medicine physician, medical physicist, radiation safety officer)
- Pre-cycle workup (biochemistry, PSA / CgA / 5-HIAA, kidney function)
- Supportive medications and consumables (anti-emetics, amino acid infusion for PRRT, hydration)
- Whether quote is per-cycle or full-course and how additional cycles are priced
- Cancellation, partial-completion, and refund terms
- Concurrent therapy continuation (ARPI, bone-targeted agents) and whether bundled or separate
- Re-staging imaging frequency and whether bundled
- Follow-up after course completion — what's covered and for how long
Centres unwilling to provide written line-itemised quotes are providing a meaningful signal about their broader governance practice. Cost transparency and clinical governance correlate.
The bottom line
- Lu-177 PSMA-617 (Pluvicto) US list price has been reported at approximately USD 42,500 per cycle pre-discount across Drugs.com, GoodRx, and NCBI/NIH public references[1][2].
- European Union pricing is reimbursement-led under national frameworks (NICE TA in England, HAS in France, G-BA in Germany, AIFA in Italy), with confidential commercial arrangements and generally low patient out-of-pocket exposure in member states with comprehensive statutory cover[13].
- Indian per-cycle costs are meaningfully lower than US list pricing, driven by isotope source (BRIT-domestic vs international vs branded), compounded vs branded product, and bundle composition; written itemised quotes are required for like-for-like comparison[4].
- Indian published institutional cohorts (Yadav et al., Basu et al.) report Lu-177 PSMA-617 response and survival outcomes consistent with international VISION-trial data using compounded preparations[18].
- Patient out-of-pocket cost is not the same as list price; the difference depends on insurance design, manufacturer assistance, and reimbursement structure in each jurisdiction.
- Cross-currency headline comparisons are misleading. The correct method is bundle-to-bundle line-itemisation with centre quality factors (AERB licensure, qualified personnel, published institutional experience, integrated multidisciplinary review) weighed alongside cost.
- Centre transparency on cost — willingness to provide a written line-itemised quote — is itself a quality marker that correlates with clinical governance and informed consent practice[26].
Important
This article reproduces published list prices and reimbursement information from primary public sources as referenced. Prices change over time and across centres; specific per-cycle and per-course costs should be obtained directly from treating centres as written itemised quotes. This article does not constitute financial, insurance, or commercial advice.
“The honest comparison of radioligand therapy cost is not a single number across currencies. It is the cost of an itemised bundle at one centre against the cost of an itemised bundle at another centre, weighed against the quality of clinical governance, the institutional experience, the dosimetry capability, and the integrated multidisciplinary review at each. A centre that provides a transparent written quote is also more likely to provide everything else that should accompany good care.”
Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI
Bundle-to-bundle cost transparency · FMRI
At FMRI Gurugram, every Lu-177 PSMA-617 and Lu-177 DOTATATE candidacy review is followed by a fully itemised written quote covering isotope source, prescribed activity, eligibility and post-administration imaging, professional fees, hospital admission, supportive medications, and follow-up. International patients receive bundle documentation appropriate for their home insurer or self-pay context.
Request itemised quote · WhatsApp +91 8800 988936
For patients & referring clinicians
Frequently asked questions
Q01
How much does Pluvicto cost in the United States?
The published cash list price of Pluvicto in the United States has been reported at approximately USD 42,500 per cycle pre-discount, supported by Drugs.com and GoodRx pricing databases [1][2]. A typical six-cycle course corresponds to approximately USD 255,000 list-price exposure pre-insurance. Actual patient out-of-pocket cost depends on Medicare or commercial insurance coverage, Novartis Patient Support assistance, deductible status, and site of care.
Q02
How much does Pluvicto cost in India?
Indian per-cycle Pluvicto / Lu-177 PSMA-617 costs are meaningfully lower than US list pricing but vary by centre, isotope source (BRIT-domestic vs international supply vs branded Pluvicto), and the bundle of services included. Specific costs should be obtained from treating centres as written itemised quotes covering isotope, professional fees, imaging, admission, and follow-up. The full framework is described in our companion article on Lu-177 PSMA cost considerations in India [4].
Q03
Why is there such a big difference between US and Indian Pluvicto costs?
Several structural reasons. First, Indian centres often deliver compounded Lu-177 PSMA-617 using Lu-177 from BRIT (domestic) or international suppliers combined with PSMA-617 precursor; US centres typically deliver branded Pluvicto. Second, US list prices reflect the US drug-pricing system (high list price, insurance negotiation, manufacturer rebates). Third, Indian regulatory and reimbursement environments differ structurally from US Medicare and commercial insurance. The clinical outcomes from compounded Indian preparations have been documented in peer-reviewed cohorts as broadly consistent with branded-product outcomes [17][18].
Q04
Is the EU price the same as the US price?
No. EU member-state pricing is set through national reimbursement frameworks rather than a single EU-wide list price. NICE in England, HAS in France, G-BA in Germany, and AIFA in Italy each conduct their own assessments and negotiate commercial arrangements (often confidential) with Novartis. Patient out-of-pocket exposure in EU member states with comprehensive statutory or national health systems is generally low or zero for the radiopharmaceutical itself [3][13][14][15].
Q05
What is Novartis Patient Support?
Novartis Patient Support is the manufacturer's eligibility-based assistance programme for US patients prescribed Pluvicto. It provides copay assistance, insurance navigation, and patient resources. Eligibility criteria, application processes, and assistance levels are documented on the Novartis Patient Support website [9]. Similar programmes exist for Lutathera. International patients should not assume manufacturer assistance is available outside the jurisdictions where these programmes operate.
Q06
Does Indian health insurance cover Lu-177 PSMA therapy?
Coverage varies by policy and insurer. Some Indian private health insurance policies cover advanced oncology including radioligand therapy, subject to coverage limits, pre-authorisation, and policy terms. Some centres have cashless arrangements with specific insurers; others operate on reimbursement basis. Patients should confirm coverage and pre-authorisation requirements with their insurer before therapy begins [24].
Q07
What about Lu-177 DOTATATE (Lutathera) cost?
Lu-177 DOTATATE (Lutathera) is the somatostatin-receptor-targeting radioligand approved for GEP-NETs based on the NETTER-1 trial. Its US list price has been reported at approximately USD 47,500 per cycle, with a typical four-cycle course. EMA-approved September 2017. Indian per-cycle costs are meaningfully lower than US list pricing, with similar drivers to Pluvicto (isotope source, compounding, bundle composition). See our neuroendocrine tumor treatment companion article for the clinical context [20][21][22].
Q08
What's included in a typical itemised radioligand therapy quote?
A clinically appropriate itemised quote should include: radiopharmaceutical source and prescribed activity per cycle, eligibility imaging (PET-CT) cost, post-administration imaging cost, hospital admission charges, professional fees (nuclear medicine physician, medical physicist), pre-cycle workup, supportive medications and consumables, whether quote is per-cycle or full-course, additional-cycle pricing, and cancellation / partial-completion terms. Centres unwilling to provide written line-itemised quotes are providing a meaningful signal about their governance practice [26].
Q09
Are travel and accommodation costs included in Indian quotes?
Typically no. Most Indian itemised quotes cover the clinical service bundle but do not include travel, accommodation for patient and caregiver across multiple cycles, intercurrent illness costs, concurrent systemic therapy continuation, specialist consultations outside the bundle, and indirect costs (caregiver time off work, lost wages). International patients should plan for these costs separately [4].
Q10
Is a lower-cost quote always a better choice?
No. A quote substantially below typical centre pricing may reflect omitted services (no eligibility PET, no post-administration imaging, no integrated multidisciplinary review), sub-optimal isotope grade or activity, or quality-of-governance shortcuts. The right comparison is bundle-to-bundle with centre quality factors weighed alongside cost: AERB licensure, qualified personnel, institutional experience, published outcomes, integrated multidisciplinary review, and quality of informed consent. Cost cannot be assessed independent of these [26].
Q11
How do Indian compounded Lu-177 PSMA outcomes compare with branded Pluvicto?
Published Indian institutional cohorts (Yadav et al., AIIMS, 2017; Basu et al., BARC; subsequent updates) using compounded Lu-177 PSMA-617 have reported PSA50 response rates and survival outcomes broadly consistent with international VISION-trial data using branded Pluvicto. The compounded preparations are produced under DCGI permissions and AERB licensure at experienced Indian centres. Clinical equivalence is supported by published cohort data; cost differs substantially [17][18].
Q12
How do I get an itemised radioligand therapy quote at FMRI?
At FMRI Gurugram, every Lu-177 PSMA-617 and Lu-177 DOTATATE candidacy review is followed by a fully itemised written quote covering isotope source, prescribed activity, eligibility and post-administration imaging, professional fees, hospital admission, supportive medications, and follow-up. International patients receive bundle documentation appropriate for their home insurer or self-pay context. WhatsApp +91 8800 988936 to begin a confidential review.
Citations & references
All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the regulatory archive — open in a new tab to verify.
[1] Drugs.com. Pluvicto Prices, Coupons, Copay Cards & Patient Assistance (price guide).
View source ↗[2] GoodRx. Pluvicto Prices, Coupons & Savings Tips.
View source ↗[3] Hennrich U, Eder M.
177Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.
Pharmaceuticals (Basel). 2022;15(10):1292.
View source ↗[4] Theranostic Physicians (TPPL) / FMRI. Lu-177 PSMA Therapy Cost Considerations in India (Patient Guide).
View source ↗[5] U.S. Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer (March 23, 2022); label expansion March 2025.
View source ↗[6] U.S. Food and Drug Administration. FDA approves Lutathera (lutetium Lu-177 dotatate) for the treatment of gastroenteropancreatic neuroendocrine tumors (January 26, 2018).
View source ↗[7] European Medicines Agency. Pluvicto EPAR — European Public Assessment Report.
View source ↗[8] National Library of Medicine (NIH) Bookshelf. Lutetium (
177Lu) Vipivotide Tetraxetan (Pluvicto). NBK596311.
View source ↗[9] Novartis Patient Support. Coverage & Support for Pluvicto patients.
View source ↗[10] Centers for Medicare & Medicaid Services (CMS). Medicare Part B coverage of physician-administered drugs.
View source ↗[11] Roviello G, Catalano M, Ravelli A, et al. Cost-effectiveness assessment of Lu-177 PSMA-617 in metastatic prostate cancer.
Cancers (Basel). 2023;15(13):3290.
View source ↗[12] European Medicines Agency. Pluvicto Summary of Product Characteristics (SmPC) and EPAR.
View source ↗[13] National Institute for Health and Care Excellence (NICE), UK. TA940: Lutetium (
177Lu) vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer (May 2024).
View source ↗[14] Haute Autorité de Santé (HAS), France. Pluvicto — avis de la Commission de la Transparence.
View source ↗[15] Gemeinsamer Bundesausschuss (G-BA), Germany. Nutzenbewertung nach §35a SGB V — Pluvicto.
View source ↗[16] Agenzia Italiana del Farmaco (AIFA), Italy. Pluvicto — classificazione e rimborsabilità.
View source ↗[17] Department of Atomic Energy, Government of India. Board of Radiation and Isotope Technology (BRIT) — Medical Isotope Production.
View source ↗[18] Yadav MP, Ballal S, Tripathi M, et al.
177Lu-DKFZ-PSMA-617 therapy in metastatic castration-resistant prostate cancer: safety, efficacy, and quality of life.
Eur J Nucl Med Mol Imaging. 2017;44(1):81-91.
View source ↗[19] European Association of Nuclear Medicine. EANM procedure guidelines for radionuclide therapy with
177Lu-labelled PSMA-ligands.
Eur J Nucl Med Mol Imaging. 2019;46(12):2536-2544.
View source ↗[20] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of
177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1).
N Engl J Med. 2017;376(2):125-135.
View source ↗[21] Drugs.com. Lutathera Prices, Coupons, Copay Cards & Patient Assistance.
View source ↗[23] Bhatnagar V, Pandey AK, Singh H, et al. Health Insurance and Out-of-Pocket Costs for Cancer Treatment in India.
Indian J Med Res. 2020;152(4):340-348.
View source ↗[24] Insurance Regulatory and Development Authority of India (IRDAI). Health insurance regulations and standardisation framework.
View source ↗[25] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION).
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[26] Atomic Energy Regulatory Board (Government of India). Safety Code for Nuclear Medicine Facilities. AERB/RF-MED/SC-2 (Rev. 2).
View source ↗[27] Basu S, Parghane RV, Banerjee S, et al. Long-term outcome of
177Lu-PSMA-617 therapy in mCRPC: Indian institutional experience.
Clin Nucl Med. 2021;46(10):820-826.
View source ↗[28] Hofman MS, Emmett L, Sandhu S, et al. [
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with mCRPC (TheraP).
Lancet. 2021;397(10276):797-804.
View source ↗[29] Indian College of Nuclear Medicine. Guidelines for accreditation and training of nuclear medicine therapy facilities in India.
View source ↗[30] Iravani A, Violet J, Azad A, et al. Lutetium-177 PSMA therapy: practical aspects, dosimetry, and outcomes.
Theranostics. 2020;10(20):8854-8866.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.